1. Long-term results of tacrolimus in orthotopic liver transplant.
2. Kinetics of IV and PO Mycophenolate Mofetil in living donor and deceased donor liver transplantation with tacrolimus.
3. Drug interactions, immunosuppressants with other drugs.
4. De novo cancers after liver transplant
5. Post-transplant lymphoproliferative disorder.
6. Pregnancy after transplantation.
7. End stage renal failure after liver transplant.
8. Ribavirin dose concentration profile in relation to renal dysfunction in post liver transplant HCV positive patients.
9. Role of Rituximab for post transplant lymphoproliferative disorder.
10. Investigational in treatment strategy with Hepatitis C vital infection in liver transplant patients.
11. Pulmonary function after liver transplant in patients with alpha 1 anti-trypsin deficiency.
12. Role of immunohistochemical markers to distinguish recurrent hepatitis C viral infection and acute rejection in post-transplant patients.
13. Outcome after liver transplant for Hepatitis C viral genotype subtypes.
14. In-vivo and In-vitro immunological markers of immunosuppression, and dose adjustment based on immunological index and equivalence of various drugs.
15. Phosphorylation of Ribavirin.
16. Development of a Tacrolimus analog with no nephrotoxicity.
17. Study of bioequivalence of different forms of Valganciclovir in post transplant patients.
18. Study and development of newer drugs for Hepatitis C viral infection, protease inhibitors and other drugs, and it’s use to prevent HCV infection in liver transplant grafts.